Company news
Xoma Royalty Corporation (NASDAQ:XOMA) news
Every Xoma Royalty Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
XOMA Royalty Announces Closing of Its Acquisition by Ligand
July 14, 2026
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
June 12, 2026
XOMA Royalty : Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date
June 11, 2026
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
April 27, 2026
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
March 18, 2026
XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
March 12, 2026
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
February 9, 2026
XOMA Royalty Announces CFO Transition
January 12, 2026
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
December 30, 2025
XOMA Royalty Declares Quarterly Preferred Stock Dividends
December 22, 2025
XOMA Royalty Enters into Agreement to Acquire Generation Bio
December 15, 2025
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
December 5, 2025
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
November 26, 2025
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
November 21, 2025
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
November 12, 2025
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
November 10, 2025
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
October 24, 2025
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
October 17, 2025
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
October 2, 2025
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
September 24, 2025
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
September 17, 2025
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
August 20, 2025
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
August 13, 2025
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
August 11, 2025
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
August 4, 2025
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
August 4, 2025
ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction
July 14, 2025
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
June 27, 2025
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
May 27, 2025
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
May 13, 2025
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
May 7, 2025
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
April 14, 2025
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
April 2, 2025
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
March 17, 2025
XOMA Royalty to Present at Investor Conferences in March
February 24, 2025
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
December 2, 2024
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
November 7, 2024
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
August 13, 2024
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
May 9, 2024
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024
XOMA Corporation Announces Closing of Tender Offer
April 3, 2024
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
March 19, 2024
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
March 8, 2024
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
February 16, 2024
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
January 18, 2024
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
January 8, 2024
XOMA Announces Stock Repurchase Program of up to $50 Million
January 2, 2024
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
November 7, 2023
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 31, 2023